Medline Third Quarter 2026 Results Conference Call - MEDLINE INC

Explicit Guidance:

• FY2026 Net Sales: Raised organic sales growth guidance to 10–10.5% (up from 9–10%), reflecting continued strong demand; guidance includes a $78 million impact from IEPA tariff-related customer repayments and excludes IEPA tariff refund benefits (noting $324 million net refunds recognized through Q3 2026).
• FY2026 Adjusted EBITDA: Reaffirmed guidance of $3.3–3.4 billion, expecting to land near the midpoint; this includes approximately $80 million in expected costs related to Middle East conflict (inflation/diesel/raw materials) and excludes the $324 million IEPA refund benefit.
• FY2027 Preliminary Framework: Expects net sales growth in the "high single digits" and adjusted EBITDA growth in the "low to mid single digits," driven by same-store sales, new customer implementations, modest pricing, and tariff favorability at current rates; this framework excludes IEPA tariff refund benefits for 2026 and 2027.
• FY2027 Margins: Anticipates adjusted EBITDA growth trailing net sales growth in 2027 due to elevated inflation (diesel, raw materials), capacity investments, and quality plan costs; expects to return to adjusted EBITDA growth at or above net sales growth in 2028.
• Restructuring Costs: Expects to incur $20–30 million in restructuring costs recorded in Q4 2026 (excluded from adjusted EBITDA), targeting $80–90 million in annualized savings, primarily realized in 2027.
• Capital Allocation: Announced a new $1 billion share repurchase program with no defined timeline; intends to execute opportunistically to fund growth, M&A, and debt paydown ($750 million term loan prepayment already completed in October) while maintaining a disciplined leverage profile (net leverage 2.5x).

Business-Segment Outlook:

• Prime Vendor Signings: On track to achieve the full-year goal of $1 billion in new customer signings; notes a record $2.4 billion signed in 2025, with revenue flow-through projected at 65% in 2026 and the remainder in 2027.
• Supply Chain Solutions (SCS): Anticipates margins remaining in the "mid-fours" for the remainder of 2026 (currently 4.4% in Q3) due to lower-margin customer mix from first-year prime vendor rebates; expects long-term margin recovery via brand conversion (10% in year one, 2–4% thereafter).
• Lab & Diagnostics: Projects penetration growth from 10% to 20% within prime vendor accounts; identifies a ~30% convertible opportunity from existing acute care lab customers, with organic growth expectations of 3–4% post-signing.
• Medline Brand: Plans to implement a "larger than usual" price increase in early Q1 2027 to offset inflationary pressures; expects brand conversion to drive margin dollar growth and customer savings.
• Customer Mix: Observes continued shift toward acute care sales and lower-margin prime vendor relationships offsetting higher-margin red line brand growth in the near term.

Market and Competitive Outlook:

• Demand Trends: Strong demand persists across acute care, non-acute care, and international channels; surgical solutions growing via kitting expansion and operating room efficiency drives; non-acute care expected to grow faster than acute long-term due to an aging population shifting care settings.
• Pricing Strategy: Pricing is not used as a growth lever but as a mechanism to mitigate COGS; intends to negotiate price increases within contract frameworks when cost realities become unsustainable for customers; notifies customers 30–60 days prior to Jan 1 and July 1 implementation dates.
• Share Shifts: Continued gaining share in surgical kitting and prime vendor implementations; business model positioned as the "value player" capable of delivering total value savings to customers.
• Operational Scale: Maintains an outsized inventory position (~80 days on hand) to ensure best-in-class service levels and fill rates; four new distribution centers (DCs) currently on the docket to support growth outpacing the market.

Macro / Industry Outlook:

• Inflation Costs: Assumes diesel prices ($6.25/gallon), raw materials, and finished goods costs remain elevated at current levels throughout 2027; increased estimate of Middle East conflict-related cost impact from $70 million to $80 million for FY2026.
• Tariffs: Assumes tariff rates remain at current levels through 2027, providing year-over-year favorability compared to prior periods; guidance excludes one-time IEPA refund benefits.
• Political Environment: No anticipated change in patient volumes or surgical activity due to recent election outcomes; believes reimbursement improvements under Democratic administration could soften impacts on Medicare/Medicaid but view core volumes as demand-driven.
• Geopolitics: Elevated Middle East conflict costs expected to weigh more heavily in Q4 2026 than Q3 as higher-cost inventory flows through cost of goods sold.

Strategic Initiatives:

• Capacity Expansion: Building four new DCs: 1.2M sq ft in Dallas-Fort Worth (announced March), 1M sq ft in Southern California (announced July), 800k sq ft in Michigan (recent), and the Tracy, CA facility opening by year-end; all include auto-store automation.
• International Expansion: Prime vendor rollout in Canada with Mohawk MedVac; currently live at five hospitals with full rollout expected by Q1 2027; adopting a "crawl, walk, run" strategy to adapt to Canadian reimbursement models.
• Quality Action Plan: Multi-year effort involving third-party assessments of 30+ manufacturing sites; investing in people, processes, and technology for remediation; exit of the home care bed business ($60M revenue) deemed a proactive safety decision made in concert with the FDA.
• Restructuring: Launched enterprise-wide program to streamline organization and reduce duplication, funding future investments via $80–90 million in annualized savings.

Risks and Headwinds to Outlook:

• Margin Pressure: Elevated input costs (diesel, raw materials, finished goods), customer mix shifts toward lower-margin prime vendor deals, and capital expenditures for automation and quality may suppress earnings growth in 2026–2027.
• Quality Assessments: Multi-year quality assessments carry inherent risk of finding additional impacts; while no further major exits are anticipated, ongoing remediation costs are baked into the 2026 numbers and growing for 2027.
• Macro Volatility: Middle East conflict costs and tariff regimes are key variables; any escalation or policy shift could alter the inflation and revenue assumptions.
• Implementation Timing: New DCs and automation (e.g., Tracy facility) face timing risks; efficiency gains from Tracy's auto-store expected to improve throughput in mid-2027.
• Contractual Constraints: Pricing power is limited by existing contract structures, potentially delaying pass-through of inflationary costs until contract renewals or specific negotiation windows.

Management Tone on the Future:

• Confidence Level: High confidence in long-term earnings power and ability to return to growth-at-or-above-sales rates in 2028; acknowledges near-term margin pressure but views investments as necessary for future resilience.
• Strategic Hedges: Deliberately investing in capacity, automation, and quality to strengthen the business model despite current margin compression; emphasizes "value player" status to navigate market softness.
• Capital Discipline: Maintains a disciplined approach to leverage with a path to investment-grade status; share buybacks are opportunistic rather than fixed-schedule.
• Forward Guidance: Provided a preliminary 2027 framework rather than strict guidance, noting it is subject to change based on market dynamics.

Miscellaneous:

• Tracy Fire Impact: Q3 net income reduced by $80 million due to the fire at the Tracy distribution center; $100 million insurance recovery recognized to date (full recovery expected over time); excluded from adjusted EBITDA.
• Free Cash Flow: Generated $1.8 billion in FCF for the first nine months of 2026, driven by net tariff benefits and favorable working capital, partially offset by CapEx ($348 million YTD).
• M&A Strategy: Unchanged; continues to pursue bolt-on acquisitions in products, channels, and services, with no deprioritization relative to organic growth.
• Q&A Clarifications: Confirmed that the $80M inflation estimate includes diesel, inbound freight, and raw materials; confirmed that brand conversion offsets price increases for customers.